No  Site  Stage of cancer   Title of study Principal investigator  Details of trial  Status
1 Breast  STAGE 4, BRAIN METS, 2nd LINE, HER2 + ASLAN001-006: A phase II single arm trial to assess the efficacy of ASLAN001 plus capecitabine in previously irradiated, progressing central nervous system (CNS) metastases for HER2 positive breast cancer patients. Dr Lee Guek Eng  NA Open 
2 Breast TNBC, non-metastatic, 1st line, neoadjuvant

MK3475-522:   A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as neoadjuvant therapy and Pembrolizumab vs Placebo as adjuvant therapy for Triple Negative Breast Cancer

Dr Rebecca Dent  NCT03036488  Open
 3 Breast HER2-, Hormone Receptor +, Advanced Breast Ca

CBYL719X2402:  A Phase II, Multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of Alpelisib plus Fulvestrant or Letrozole based on prior endocrine therapy, in patients with PIK3CA mutant hormone receptor (HR) positive, Her2-negative advanced breast cancer (aBC), who progressed on or after CDK 4/6 inhibitor treatment.

 Dr Yap Yoon Sim  NCT03056755  Open
 4 Breast LA or MBC TNBC and HR(+) HER2 (-), 1st Line for LA/MBC CO40016-IPATunity: A double Blind, Placebo-Controlled Randomized Phase III Study of Ipatasertib in combination with Paclitaxel as a Treatment for patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer  Dr Rebecca Dent NCT03337724 Open 
 5 Breast Inoperable LA/MBC, TNBC MO39193-IMPASSION132: Phase III, Randomized, Double –Blind,Placebo-Controlled Multicenter study of the sfficacy and safety of Atezolizumab in combination with chemotherapy for patients with early relapsing recurrent (Inoperable Loacally Advanced or Metastatic) Triple-Negative Breast Cancer.  Dr Rebecca Dent NCT03371017 Open 
 6 Breast High risk Early stage BC, HR (+) HER 2(-) MonarchE: Protocol I3Y-MC-JPCF: A Randomized, open-label, Phase 3 study of Abemaciclib combined with standard adjuvant endocrine therapy versus standard endocrine therapy alone in patients with high risk, node positive, early stage, Hormone Receptor positive, Human Epidermal Receptor 2 Negative, Breast Cancer  Dr Yap Yoon Sim  NCT03155997  Open
 7 Breast HR (ER and/or PgR) positive, MBC ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane.  Dr Elaine Lim NCT03326674 Open
 8 Breast HER2-,  Hormone Receptor +, Advanced Breast Cancer PATHWAY: A Randomized, Double Blind, Placebo Controlled, Phase 3 Trial of Tamoxifen + Goserelin With or Without Palbociclib in Women with Hormone Receptor Positive, HER2 Negative Locoregionally Recurrent or  Metastatic Breast Cancer Dr Yap Yoon SIm NCT03423199  Open


Last updated on Jun 2018.